Bipolar News From Medical News TodayLatest Bipolar News From Medical News Today.ABILIFY(R) (aripiprazole) Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar Disorder And Schizophrenia- May 19, 2008 Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of Schizophrenia in adolescents (aged 13-17).http://www.medicalnewstoday.com/articles/107901.php FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder- May 16, 2008 AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder1,2.http://www.medicalnewstoday.com/articles/107611.php Perceptual Switch Rates With Ambiguous Structure-from-motion Figures In Bipolar Disorder- May 13, 2008 Most people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood Earlier research suggested that people with bipolar mood disorder might alternate their perception more slowly when looking at ambiguous figures.http://www.medicalnewstoday.com/articles/107163.php Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting- May 9, 2008 Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts 44 and 80).http://www.medicalnewstoday.com/articles/106843.php Problems Identified With Diagnosis Of Bipolar Disorder- May 7, 2008 A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).http://www.medicalnewstoday.com/articles/106597.php |